Abstract: Abstract Background Fibrosis regression has been associated with nucleoside analogue (NA) treatment in chronic hepatitis B (CHB) patients. Although non-invasive fibrosis markers have been evaluated in CHB, their utility for monitoring on-treatment histologic regression has not been evaluated. Aims To characterize improvements in disease severity and the utility of non-invasive biomarkers in CHB NA treated patients. Methods Histology, labs, AST-to-platelet ratio index, and Fibrosis-4 (Fib-4) from treatment-naive CHB patients were evaluated at ba...
(read more)
Topics: 
Internal medicine
Gastroenterology